OPKO Health Announces Dosing of First Subject in Phase 1 Clinical Study of a Long-Acting Oxyntomodulin for the Treatment of Obesity and Type II Diabetes Mar 16, 2016
OPKO 4Kscore® Recommended in 2016 European Association of Urology Prostate Cancer Guidelines Mar 15, 2016
OPKO’s GeneDx Presenting on a Number of Topics at the 2016 ACMG Annual Clinical Genetics Meeting Mar 2, 2016
OPKO's GeneDx Participating in the Molecular Medicine Tri-Conference 2016 in San Francisco Feb 24, 2016
OPKO Health Announces Dosing of First Patient in Phase 2a Clinical Study of a Long-Acting Factor VIIa for the Treatment of Hemophilia Feb 23, 2016
OPKO to Announce 2015 Fourth Quarter and Full Year Financial Results on February 29, 2016 Feb 23, 2016
